Cohen Capital Management Inc. Takes Position in Illumina, Inc. (NASDAQ:ILMN)

Cohen Capital Management Inc. purchased a new stake in Illumina, Inc. (NASDAQ:ILMN) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 1,742 shares of the life sciences company’s stock, valued at approximately $233,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of ILMN. Golden State Wealth Management LLC purchased a new stake in shares of Illumina in the 4th quarter worth $32,000. Versant Capital Management Inc raised its holdings in shares of Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after acquiring an additional 146 shares in the last quarter. TD Private Client Wealth LLC lifted its stake in Illumina by 58.5% in the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock worth $50,000 after acquiring an additional 141 shares during the period. V Square Quantitative Management LLC grew its holdings in Illumina by 50.6% during the 4th quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company’s stock worth $52,000 after acquiring an additional 132 shares in the last quarter. Finally, First Horizon Advisors Inc. increased its position in Illumina by 73.5% during the 4th quarter. First Horizon Advisors Inc. now owns 439 shares of the life sciences company’s stock valued at $59,000 after purchasing an additional 186 shares during the period. Institutional investors own 89.42% of the company’s stock.

Illumina Trading Down 3.1 %

NASDAQ ILMN opened at $94.20 on Friday. Illumina, Inc. has a 12-month low of $93.50 and a 12-month high of $156.66. The company has a fifty day simple moving average of $127.98 and a two-hundred day simple moving average of $134.13. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The stock has a market cap of $14.92 billion, a P/E ratio of -12.27, a P/E/G ratio of 1.60 and a beta of 1.10.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on ILMN shares. Royal Bank of Canada lowered their price target on shares of Illumina from $250.00 to $247.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Robert W. Baird upped their target price on Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Canaccord Genuity Group dropped their target price on Illumina from $145.00 to $135.00 and set a “hold” rating on the stock in a research report on Friday, February 7th. JPMorgan Chase & Co. boosted their price target on Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, Piper Sandler raised their price objective on Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $159.45.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.